These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 10629734)

  • 1. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
    Ochs A
    Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA review divisions: performance levels and the impact on drug sponsors.
    Milne CP; Kaitin KI
    Clin Pharmacol Ther; 2012 Mar; 91(3):393-404. PubMed ID: 22336592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 7. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 8. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA's proposed rules on patent listing requirements for new drug and 30-month stays on ANDA approval (proposed Oct. 24, 2002).
    Hui YF
    Ann Health Law; 2003; 12(2):325-40, table of contents. PubMed ID: 12856462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 12. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 15. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J
    Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
    [No Abstract]   [Full Text] [Related]  

  • 16. The FDA's regulation of pharmaceutical communications in the context of managed care: a suggested approach.
    Kuhlik BN
    Food Drug Law J; 1995; 50(1):23-48. PubMed ID: 10342984
    [No Abstract]   [Full Text] [Related]  

  • 17. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

  • 18. Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.
    Joffe S; Lynch HF
    N Engl J Med; 2018 Feb; 378(8):695-697. PubMed ID: 29320302
    [No Abstract]   [Full Text] [Related]  

  • 19. Highlights and a hidden hazard--the FDA's new labeling regulations.
    Avorn J; Shrank W
    N Engl J Med; 2006 Jun; 354(23):2409-11. PubMed ID: 16760439
    [No Abstract]   [Full Text] [Related]  

  • 20. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 33.